4-(c2-6alkoxy)-substituted chalcones as therapeutic agents
ALK 2-6B2B3B4B5 1 2 1-45-20A3 E22E 1-63-205-20 The present invention pertains to compounds of the following formula: (1) wherein: Ris primary or secondary aliphatic saturated Calkyl; each of R, R, R, and Ris independently -H, -OH, or -OMe; each of Rand Ris independently: -H, optionally substituted C...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Potter, Gerard Andrew Ijaz, Taeeba |
| description | ALK 2-6B2B3B4B5 1 2 1-45-20A3 E22E 1-63-205-20 The present invention pertains to compounds of the following formula: (1) wherein: Ris primary or secondary aliphatic saturated Calkyl; each of R, R, R, and Ris independently -H, -OH, or -OMe; each of Rand Ris independently: -H, optionally substituted Calkyl, or optionally substituted Caryl; Ris -H, -OH, -OC(═O)R, -OS(═O)OH, or -OP(═O)(OH); Ris: -H, optionally substituted Calkyl, optionally substituted Cheterocyclyl, or optionally substituted Caryl; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for both diagnosis and treatment of, for example, proliferative conditions, such as cancer, and inflammatory conditions |
| format | Patent |
| fullrecord | <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_07112698</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>07112698</sourcerecordid><originalsourceid>FETCH-uspatents_grants_071126983</originalsourceid><addsrcrecordid>eNrjZLAy0dVINtI1S8zJzq-o1NQtLk0qLsksKS1JTVFIzkjMSc7PSy1WSCxWKMlILUosSC0tyUxWSExPzSsp5mFgTUvMKU7lhdLcDApuriHOHrqlxQWJJSAV8elFiSDKwNzQ0MjM0sKYCCUA53ovZg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>4-(c2-6alkoxy)-substituted chalcones as therapeutic agents</title><source>USPTO Issued Patents</source><creator>Potter, Gerard Andrew ; Ijaz, Taeeba</creator><creatorcontrib>Potter, Gerard Andrew ; Ijaz, Taeeba ; Spear Therapeutics Limited</creatorcontrib><description>ALK 2-6B2B3B4B5 1 2 1-45-20A3 E22E 1-63-205-20 The present invention pertains to compounds of the following formula: (1) wherein: Ris primary or secondary aliphatic saturated Calkyl; each of R, R, R, and Ris independently -H, -OH, or -OMe; each of Rand Ris independently: -H, optionally substituted Calkyl, or optionally substituted Caryl; Ris -H, -OH, -OC(═O)R, -OS(═O)OH, or -OP(═O)(OH); Ris: -H, optionally substituted Calkyl, optionally substituted Cheterocyclyl, or optionally substituted Caryl; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for both diagnosis and treatment of, for example, proliferative conditions, such as cancer, and inflammatory conditions</description><language>eng</language><creationdate>2006</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7112698$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,776,798,881,64012</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7112698$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Potter, Gerard Andrew</creatorcontrib><creatorcontrib>Ijaz, Taeeba</creatorcontrib><creatorcontrib>Spear Therapeutics Limited</creatorcontrib><title>4-(c2-6alkoxy)-substituted chalcones as therapeutic agents</title><description>ALK 2-6B2B3B4B5 1 2 1-45-20A3 E22E 1-63-205-20 The present invention pertains to compounds of the following formula: (1) wherein: Ris primary or secondary aliphatic saturated Calkyl; each of R, R, R, and Ris independently -H, -OH, or -OMe; each of Rand Ris independently: -H, optionally substituted Calkyl, or optionally substituted Caryl; Ris -H, -OH, -OC(═O)R, -OS(═O)OH, or -OP(═O)(OH); Ris: -H, optionally substituted Calkyl, optionally substituted Cheterocyclyl, or optionally substituted Caryl; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for both diagnosis and treatment of, for example, proliferative conditions, such as cancer, and inflammatory conditions</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2006</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNrjZLAy0dVINtI1S8zJzq-o1NQtLk0qLsksKS1JTVFIzkjMSc7PSy1WSCxWKMlILUosSC0tyUxWSExPzSsp5mFgTUvMKU7lhdLcDApuriHOHrqlxQWJJSAV8elFiSDKwNzQ0MjM0sKYCCUA53ovZg</recordid><startdate>20060926</startdate><enddate>20060926</enddate><creator>Potter, Gerard Andrew</creator><creator>Ijaz, Taeeba</creator><scope>EFH</scope></search><sort><creationdate>20060926</creationdate><title>4-(c2-6alkoxy)-substituted chalcones as therapeutic agents</title><author>Potter, Gerard Andrew ; Ijaz, Taeeba</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_071126983</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2006</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Potter, Gerard Andrew</creatorcontrib><creatorcontrib>Ijaz, Taeeba</creatorcontrib><creatorcontrib>Spear Therapeutics Limited</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Potter, Gerard Andrew</au><au>Ijaz, Taeeba</au><aucorp>Spear Therapeutics Limited</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>4-(c2-6alkoxy)-substituted chalcones as therapeutic agents</title><date>2006-09-26</date><risdate>2006</risdate><abstract>ALK 2-6B2B3B4B5 1 2 1-45-20A3 E22E 1-63-205-20 The present invention pertains to compounds of the following formula: (1) wherein: Ris primary or secondary aliphatic saturated Calkyl; each of R, R, R, and Ris independently -H, -OH, or -OMe; each of Rand Ris independently: -H, optionally substituted Calkyl, or optionally substituted Caryl; Ris -H, -OH, -OC(═O)R, -OS(═O)OH, or -OP(═O)(OH); Ris: -H, optionally substituted Calkyl, optionally substituted Cheterocyclyl, or optionally substituted Caryl; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for both diagnosis and treatment of, for example, proliferative conditions, such as cancer, and inflammatory conditions</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_uspatents_grants_07112698 |
| source | USPTO Issued Patents |
| title | 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T13%3A56%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Potter,%20Gerard%20Andrew&rft.aucorp=Spear%20Therapeutics%20Limited&rft.date=2006-09-26&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E07112698%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |